MED-EL Launches World’s First Commercially Available Totally Invisible Cochlear Implant
29.9.2026 14:00:00 CEST | news aktuell GmbH | Press Release
- World's first and only commercially available cochlear implant with all components implanted beneath the skin
- Continuous hearing day and night
- Hearing performance designed to be the same as established cochlear implant solutions
September 29, 2026 – (Innsbruck, Austria): MED-EL, a global leader in hearing implant technology, today announced the launch of TICI UNICO, the world's first and only commercially available totally invisible cochlear implant. Designed for people with severe-to-profound hearing loss, TICI UNICO enables continuous hearing 24 hours a day while remaining completely beneath the skin. It has received CE Mark approval and is being introduced in European markets.

Cochlear implants have helped hundreds of thousands of people worldwide to hear. TICI UNICO expands hearing implant options by combining continuous hearing with complete invisibility and freedom from external audio processors. Users can hear while sleeping, exercising, showering, swimming and charging the device.
"TICI UNICO is a new chapter in the history of hearing," says Dr. Ingeborg Hochmair, co-founder and CEO of MED-EL. "For the first time, invisible hearing with a cochlear implant is possible. This is a milestone for people with hearing loss and the result of decades of research and innovation at MED-EL.”
Key benefits of TICI UNICO:
- Completely invisible
- 24/7 access to sound
- No external equipment to wear, remove, or maintain
- No concerns about losing or damaging external devices
- Hearing performance comparable to established cochlear implant solutions
Long-Held Vision becomes Reality
Capturing sound through the skin has long been one of the greatest challenges in developing a totally invisible cochlear implant. MED-EL successfully developed an innovative microphone technology designed to deliver high-quality sound while remaining completely beneath the skin.
Prof. Philippe Lefèbvre, Head of the ENT Department at CHU Liège, and Prof. Joachim Müller, Associate Professor for Otology and Cochlear Implants at LMU University Hospital Munich, highlight the significance of TICI UNICO: “Twenty-four-hour, invisible hearing opens the door to a completely new generation of hearing implants.”
For recipients, the impact extends to the freedom of hearing. Thomas, one of the first TICI UNICO recipients, says: ”I wake up hearing, fall asleep hearing, and can enjoy everyday moments without having to think about my hearing device.”
TICI UNICO is intended for people with severe-to-profound sensorineural hearing loss who may benefit from a cochlear implant. More information: http://go.medel.com/tici.
Contacts
Silke ArtnerPR & Corporate Communications
Tel:+43 577880press@medel.comwww.medel.com/press-roomImages
About MED-EL
The Austrian-based, privately owned company MED-EL was co-founded by cochlear implant pioneers Ingeborg and Erwin Hochmair. To date, MED-EL has more than 3,300 employees from around 90 nations and 30 locations worldwide.
Users in 142 countries hear with a MED-EL device. www.medel.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
DRF Aviation Services launches on October 1, 20261.10.2026 11:28:06 CEST | Press Release
DRF Luftrettung and DRF Maintenance are joining forces: the newly established DRF Aviation Services combines the two companies’ technical expertise built on more than 50 years of experience in helicopter maintenance, modifications and services. As a “one-stop shop”, DRF Aviation Services provides the full range of services from a single source. Helicopter operators benefit from high levels of reliability and innovative capability.
RM Equity Partners (RMEP) completes generational handover – partners take full ownership1.10.2026 09:30:11 CEST | Press Release
Ruggell (LI), 1 October 2026 – RM Equity Partners (RMEP), the international investment firm focused on asset-light digital businesses, today announces the completion of its generational handover. As of 1 October 2026, the management company is fully owned by the three partners Eugen Benedikt Russ, Chris Wittlinger and Nicola Szekely and the wider team, who will make all new investments independently. With this step, the succession within the founding family is concluded: RMEP operates as a fully independent investment firm with no ownership, management or personnel ties to the Russmedia group. RMEP has grown into one of the most active investors in digital marketplaces, software and consumer platforms in Europe: Assets under management of more than €500 million Annual investment capacity of more than €100 million 50+ portfolio investments, with 95% of revenue generated outside Austria Independent evergreen structure – the partners invest their own capital (principal investing, no exter
Global Sales of Professional Service Robots Surge 24%30.9.2026 12:05:00 CEST | Press Release
7,000 Humanoids emerge as new market 117,000 Transport and logistics’ robots lead as top application
German pharmacies offering new services: Statistical Yearbook 2026 out now30.9.2026 10:29:22 CEST | Press Release
Berlin / Germany, 30 September 2026 – ABDA – Federal Union of German Associations of Pharmacists has published its Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2026”. The 132-page publication provides a comprehensive overview of the most important facts and statistics of the pharmacy market as well as information on the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond.
Grünenthal partners with DKSH to bring four important pain medicines to eight new markets in Asia-Pacific28.9.2026 09:07:45 CEST | Press Release
The partnership will bring Qutenza®, Vimovo®, Palexia® and Zomig® to people living with pain in Asia-Pacific, spanning Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam. Pain is a significant healthcare challenge in the region, due to the ageing population and the high burden of chronic diseases.[i],[123], The partnership is a key step in Grünenthal’s strategy to enhance patient care and expand access to its innovative medicines.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

